Opthea's inclusion in S&P/ASX 300 Index

Opthea Limited (ASX:OPT) has announced its addition to the S&P/ASX 300 Index, effective Monday, September 23, 2024. This reflects the Company's strengthened balance sheet with proceeds from the recent financing completed in July 2024 and the completion of enrollment of close to 2,000 patients in the sozinibercept Phase 3 wet AMD program.

Executive Commentary on Opthea's Inclusion in S&P/ASX 300 Index

Opthea's Chief Executive Officer, Frederic Guerard, stated, 'Opthea's addition to the S&P/ASX 300 Index reflects the Company's strengthened balance sheet with proceeds from the recent financing completed in July 2024. We also reached a significant milestone by completing enrollment of close to 2,000 patients in the sozinibercept Phase 3 wet AMD program. We believe our inclusion in the S&P/ASX 300 Index may further diversify the Company's institutional shareholder base as we progress our Phase 3 pivotal program to anticipated topline data readouts of COAST in early Q2 calendar year 2025 and ShORe in mid calendar year 2025 and prepare the organization for a potential US FDA approval and launch.'

Summary of Opthea's Inclusion in S&P/ASX 300 Index

Opthea (ASX:OPT) has joined the S&P/ASX 300 Index, signifying a strengthened balance sheet and the completion of enrollment of close to 2,000 patients in the sozinibercept Phase 3 wet AMD program. The Company anticipates topline data readouts of COAST in early Q2 calendar year 2025 and ShORe in mid calendar year 2025, preparing for a potential US FDA approval and launch. Opthea's inclusion in the S&P/ASX 300 Index may further diversify the Company's institutional shareholder base as it progresses its Phase 3 pivotal program.